Get the app
US › Healthcare

Longeveron LLC (LGVN)

US · Healthcare · Biotechnology

$2.71-59.43%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$287,000
Revenue YoY
-9.2%
Net profit
$-6.1M
EPS
$-0.19
EPS estimate
$-0.19
Net margin
-2,116.0%

EPS came in at -0.19 against a street estimate of -0.19 — a beat of 0.0%.

Key statistics

Market cap
$21.3M
Forward P/E
0.0
P/B
2.10
Book value
$3.28
EPS (TTM)
$-10.00
52-week high
$12.30
52-week low
$2.70
50-day MA
$6.89
200-day MA
$7.22
Beta
-0.26

Analyst view

Analysts rate Longeveron LLC a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $71.50.

Shareholding

Insiders
15.14%
Institutions
20.55%

Largest institutional holders

FundStake
Millennium Management LLC4.27%
Logos Global Management LP4.06%
Vanguard Capital Management, LLC1.71%
BlackRock Inc0.71%
Geode Capital Management, LLC0.64%
ADAR1 Capital Management LLC0.63%
Jane Street Group LLC0.59%
HRT FINANCIAL LLC0.37%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Longeveron LLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.